Dyslipidemia Drugs Market at US$ 11.8 Bn in 2018 and is projected to expand at a CAGR of 3.5% from 2019 to 2030

The dyslipidemia drugs market  for the historical period 2017–2018 and forecast period 2019–2030, increasing prevalence of population with cholesterol and triglyceride abnormalities is anticipated to drive the global dyslipidemia drugs market

According to the report, the global dyslipidemia drugs market was valued at US$ 11.8 Bn in 2018 and is projected to expand at a CAGR of 3.5% from 2019 to 2030

Get the sample copy of report@ https://qyresearchmedical.com/sample/111908

Key Driver

Prevalence of cholesterol and triglyceride abnormalities is expected to increase exponentially across the world due to change in lifestyle and various factors such as obesity, lack of exercise, and poor dietary habits.

According to various government and private organizations operating in the cholesterol drugs industry, prevalence of dyslipidemia is rapidly increasing across the globe and is considered one of the serious cardiovascular conditions.

The Centers for Disease Control and Prevention (CDC) stated that around 95 million adults in the U.S. (55% of the total population) have total cholesterol levels higher than 200 mg/dL as of 2016. Furthermore, an estimated 29 million adult in U.S. have total cholesterol levels higher than 240 mg/dL.

Thus, the large population base suffering is expected to drive the global dyslipidemia drugs market during the forecast period.

Rising disease awareness through promotional activities

Several private and government organizations and key companies are actively engaged in increasing awareness about dyslipidemia through organizing various awareness campaigns or publishing guidelines for the same.

For instance, the National Lipid Association introduced “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia”, aiming to provide guidelines for dyslipidemia patients related to cholesterol lowering drug therapy.

In October 2013, Pfizer, Inc. organized Dyslipidemia Awareness and Treatment program in collaboration with the International Atherosclerosis Society. The primary objective of this event was to improve treatment care for cardiovascular patients, particularly focused on dyslipidemia. These programs would increase awareness about dyslipidemia conditions among the patient population, leading to market growth.

Discontinuation of novel dyslipidemia drugs to Hamper Market

Discontinuation of under-development drug compounds such as dalcetrapib and Saroglitazar has hindered the growth of the market.

For example, in March 2017, Zydus Discovery DMCC suspended its study for safety and efficacy of Saroglitazar Magnesium in patients with dyslipidemias due to recruitment issues.

In May 2012, F. Hoffmann-La Roche Ltd. presented an update on phase III study of dalcetrapib (dal-OUTCOMES Phase III trial) to the independent Data and Safety Monitoring Board (DSMB). However, DSMB recommended discontinuation of the clinical trial due to the lack of clinical efficacy of the drug.

Global Dyslipidemia Drugs Market: Competitive Landscape

This report profiles major players in the global dyslipidemia drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Leading players operating in the global dyslipidemia drugs market are

• Shionogi & Co., Ltd.
• Pfizer, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bayer AG
• Bristol-Myers Squibb Company
• Mylan N.V.
• Amgen, Inc.
• AstraZeneca plc
• Abbott Laboratories.

Key Questions Answered in Dyslipidemia Drugs Market Report

• What is the scope of growth of companies in the dyslipidemia drugs market?
• What will be the Y-o-Y growth of the dyslipidemia drugs market between 2019 and 2027?
• What is the influence of changing trends in drug research and development on the global dyslipidemia drugs market?
• Will North America continue to remain the most profitable regional market for dyslipidemia drugs providers?
• Which factors are anticipated to impede the growth of the global dyslipidemia drugs market during the forecast period?
• Which are the leading companies in the global dyslipidemia drugs market?

Global Dyslipidemia Drugs Market – Segmentation

Drug Class

• Statins
• Bile Acid Resins
• Fibric Acid and Omega-3 Fatty Acid Derivatives
• Niacins
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111908/2900